Prime Medicine (PRME) EPS (Weighted Average and Diluted) (2021 - 2026)
Prime Medicine (PRME) reported EPS (Weighted Average and Diluted) of -$0.28 for Q1 2026, up 30.0% on a YoY basis from -$0.22 in Q1 2025, and down 16.67% quarter-over-quarter from -$0.24 in Q4 2025.
Prime Medicine (PRME) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Prime Medicine has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$0.28 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 30.0% year-over-year to -$0.28; the trailing twelve-month figure through Mar 2026 stood at -$1.25 (up 22.36% YoY), and the FY2025 full-year result was -$1.35, up 18.18% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.28, down from -$0.24 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.72 in Q4 2022, with the low at -$1.76 in Q2 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.57 across 5 years, with a median of -$0.44 in 2023.
- Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) surged 116.18% — and 2023, when it slumped 200.0%.
- Prime Medicine's EPS (Weighted Average and Diluted) stood at $0.72 in 2022, then tumbled by 200.0% to -$0.72 in 2023, then jumped by 56.94% to -$0.31 in 2024, then grew by 22.58% to -$0.24 in 2025, then fell by 16.67% to -$0.28 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.28 (Q1 2026), -$0.24 (Q4 2025), and -$0.32 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Prime Medicine | 572.02 Mn | 572.02 Mn | - | -0.28 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.28 |
| Dec 31, 2025 | -0.24 |
| Sep 30, 2025 | -0.32 |
| Jun 30, 2025 | -0.41 |
| Mar 31, 2025 | -0.40 |
| Dec 31, 2024 | -0.31 |
| Sep 30, 2024 | -0.44 |
| Jun 30, 2024 | -0.46 |
| Mar 31, 2024 | -0.44 |
| Dec 31, 2023 | -0.72 |
| Sep 30, 2023 | -0.55 |
| Jun 30, 2023 | -0.47 |
| Mar 31, 2023 | -0.44 |
| Dec 31, 2022 | 0.72 |
| Sep 30, 2022 | -1.61 |
| Jun 30, 2022 | -1.76 |
| Mar 31, 2022 | -1.58 |
| Dec 31, 2021 | -4.45 |
| Sep 30, 2021 | -1.52 |